This peer-reviewed publication in a top-tier journal significantly de-risks the BLA submission planned for Q4 2026. The 30% DFS improvement with favorable safety profile positions aglatimagene as a potential new standard-of-care addition to radiotherapy in intermediate-to-high-risk localized prostate cancer. Monitor for BLA acceptance and any partnership discussions ahead of submission.
Price Chart
Executive Summary
Candel Therapeutics announced publication of its pivotal Phase 3 trial results for aglatimagene (CAN-2409) in localized prostate cancer in The Lancet Oncology, showing a 30% improvement in disease-free survival (HR 0.70, p=0.016) and a 38% improvement in prostate cancer-specific DFS (HR 0.62, p=0.0046). The company plans to submit a BLA in Q4 2026, supported by this peer-reviewed validation and extended follow-up data showing a 39% improvement in prostate cancer-specific DFS at a median 58-month follow-up.
Key Facts
- Phase 3 trial met primary endpoint: 30% improvement in DFS (HR 0.70, 95% CI 0.52-0.94, p=0.016)
- 38% improvement in prostate cancer-specific DFS (HR 0.62, 95% CI 0.44-0.87, p=0.0046)
- 80% negative biopsy rate at 2 years in aglatimagene arm vs 63% placebo (p=0.0018)
- Extended follow-up (median 58 months) showed 39% improvement in prostate cancer-specific DFS
- BLA submission planned for Q4 2026
- Published in The Lancet Oncology (impact factor 35.9)
- Trial enrolled 745 patients under FDA Special Protocol Assessment
- Fast Track and Regenerative Medicine Advanced Therapy designations from FDA
Financial Impact
Potential multi-hundred-million to billion-dollar market opportunity in localized prostate cancer; BLA submission in Q4 2026 de-risks regulatory path for a first-in-class immunotherapy
Risk Factors
- BLA submission and FDA review carry inherent regulatory risk; approval not guaranteed
- Competition from other localized prostate cancer therapies (e.g., focal therapy, ADT combinations)
- Commercial adoption depends on physician education and reimbursement; Candel has no commercial infrastructure
- Clinical-stage company with no approved products; capital requirements for launch may require dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3305133 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 1, 2026 26d ago | Press Release | $10.16 | awaiting T+60 | — | $8.20 (−19.24%) |
Sep 30, 2026 27d ago | Press Release | $10.44 | awaiting T+60 | — | $8.20 (−21.41%) |
Sep 10, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $8.20 (−27.58%) |
Sep 9, 2026 6w ago | 8-K | $11.33 | awaiting T+60 | — | $8.20 (−27.58%) |
Aug 15, 2026 10w ago | Institutional Cluster | $12.16 | awaiting T+60 | — | $8.20 (−32.52%) |
Aug 13, 2026 10w ago | 8-K | $11.80 | awaiting T+60 | — | $8.20 (−30.47%) |
Aug 13, 2026 10w ago | Press Release | $11.80 | awaiting T+60 | — | $8.20 (−30.47%) |
Aug 3, 2026 12w ago | Press Release | $10.07 | awaiting T+60 | — | $8.20 (−18.52%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.20 (−16.53%) |
Jul 1, 2026 16w ago | Insider Cluster | $9.83 $11.19 | ▲ +13.84% | ▲ +11.04% | $8.20 (−16.53%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers